- $99.43bn
- $118.21bn
- £31.38bn
- 92
- 66
- 99
- 98
REG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK enters agreement to acquire IDRx, Inc.
AnnouncementREG - GSK PLC - Shingrix fully liquid accepted for US FDA review
AnnouncementREG - GSK PLC - GSK ADC gets FDA breakthrough therapy designation
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
AnnouncementREG - GSK PLC - GSK’s Nucala approved in China for use in CRSwNP
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - Official List - Official List Notice
AnnouncementREG - Stock Exch Notice - Admission to Trading - 23/12/2024
AnnouncementREG - GSK PLC - Block Listing Application
AnnouncementREG - GSK PLC - Headline results from phase III FIRST trial
AnnouncementREG - GSK PLC - EMA grants PRIME Designation for GSK’227
AnnouncementREG - GSK PLC - Jemperli receives US FDA breakthrough designation
AnnouncementREG - GSK PLC - Jemperli receives positive CHMP opinion
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Overall survival data presented for Blenrep
AnnouncementREG - GSK PLC - Blenrep combination China filing acceptance
AnnouncementREG - GSK PLC - Nucala COPD submission accepted by US FDA
Announcement